Related Experiment Videos
Cardiovascular drug highlight: hirudin.
1Pharmacy Department, Montefiore Medical Center, Bronx, New York 10467, USA.
Heart Disease (Hagerstown, Md.)
|November 27, 2001
Summary
Recombinant hirudin (r-hirudin), a potent thrombin inhibitor, shows promise for treating thromboembolic complications. Clinical trials highlight its benefits, particularly for heparin-induced thrombocytopenia, leading to FDA approval of lepirudin.
Area of Science:
- Biochemistry
- Pharmacology
- Hematology
Background:
- Hirudin is a potent, naturally occurring thrombin inhibitor derived from medicinal leech saliva.
- Recombinant hirudin (r-hirudin) is now available for therapeutic applications.
- Hirudin effectively inhibits both fluid-phase and clot-bound thrombin.
Purpose of the Study:
- To review clinical trial results of hirudin in managing thromboembolic complications.
- To assess the therapeutic potential of r-hirudin in specific patient populations.
- To provide an overview of hirudin's efficacy in coronary artery disease, heparin-induced thrombocytopenia, and orthopedic surgery.
Main Methods:
- Review of selected clinical trials involving hirudin.
- Analysis of hirudin's pharmacokinetic and pharmacodynamic properties.
- Evaluation of clinical outcomes in patients treated with r-hirudin.
Main Results:
- Hirudin demonstrates significant potential in managing various thromboembolic conditions.
- Clinical benefits are most pronounced in patients with heparin-induced thrombocytopenia.
- Lepirudin, a form of r-hirudin, received FDA approval for specific anticoagulation needs.
Conclusions:
- Recombinant hirudin is a valuable therapeutic agent for thromboembolic disorders.
- The efficacy of r-hirudin is well-established in heparin-induced thrombocytopenia.
- Further research may expand the clinical applications of hirudin-based anticoagulation.